Clariane


Reiterated outlook backed by a buoyant Q1

26/04/24 -"Clariane reported 7.4% growth in its Q1 statutory and organic revenue, with the dynamism being witnessed in all the segments and regions. The financial objectives were maintained. Regarding the ..."

Pages
62
Language
English
Published on
26/04/24
You may also be interested by these reports :
14/05/24
We have maintained our assumptions based on the company’s planned €300m recap to be completed by the end of this year, but with an expected ...

14/05/24
Q1 profitability surpassed the consensus’ estimates. The top-line performance was supported by both segments and the ‘core’ operating margin was ...

14/05/24
Sonova reported decent H2 2023-24 results, which were largely in line with the company-compiled consensus. Mid-single-digit growth was led by the ...

13/05/24
DiaSorin started 2024 on a promising note with sales and profitability exceeding expectations. Healthy growth across segments was offset by waning ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO